- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Salt substitute.
Displaying page 1 of 1.
EudraCT Number: 2013-004954-58 | Sponsor Protocol Number: 2013-617 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Bispebjerg University Hospital | |||||||||||||
Full Title: Near infrared imaging and measurement of extremity lymphatic collector function using indocyanine green | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001467-22 | Sponsor Protocol Number: A6181040 | Start Date*: 2004-10-26 |
Sponsor Name:Pfizer S.A. | ||
Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER | ||
Medical condition: Histologically proven NSCLC (Stage IV or recurrent disease or locally advanced [Stage IIIB]) that is not amenable to surgery, radiation, or combined modality therapy with curative intent | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001161-41 | Sponsor Protocol Number: BRF113928 | Start Date*: 2012-09-20 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-smal... | |||||||||||||
Medical condition: Advanced non-small cell lung cancer and BRAF mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NO (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000057-20 | Sponsor Protocol Number: HC-G-H-1209 | Start Date*: 2015-11-10 | ||||||||||||||||
Sponsor Name:B. Braun Melsungen AG | ||||||||||||||||||
Full Title: PROSPECTIVE, RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTI-CENTRIC, INTERNATIONAL, STUDY ON THE EFFICACY AND SAFETY OF AN EARLY TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A BALANCED GEL... | ||||||||||||||||||
Medical condition: Hypovolaemia in Severe Sepsis / Septic Shock | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
